Literature DB >> 25093518

Tuberous sclerosis-associated renal cell carcinoma: a clinicopathologic study of 57 separate carcinomas in 18 patients.

Juan Guo1, Maria S Tretiakova, Megan L Troxell, Adeboye O Osunkoya, Oluwole Fadare, Ankur R Sangoi, Steven S Shen, Antonio Lopez-Beltran, Rohit Mehra, Amer Heider, John P Higgins, Lara R Harik, Xavier Leroy, Anthony J Gill, Kiril Trpkov, Steven C Campbell, Christopher Przybycin, Cristina Magi-Galluzzi, Jesse K McKenney.   

Abstract

Tuberous sclerosis complex (TSC) is an autosomal dominant disorder with characteristic tumors involving multiple organ systems. Whereas renal angiomyolipoma (AML) is common in TSC, renal cell carcinoma (RCC) is rarely reported. Fifty-seven RCCs from 13 female and 5 male TSC patients were reviewed. Age at surgery ranged from 7 to 65 years (mean: 42 y). Nine patients (50%) had multiple synchronous and/or metachronous RCCs (range of 2 to 20 RCCs) and 5 had bilateral RCCs (28%). Seventeen patients (94%) had histologically confirmed concurrent renal AMLs, including 15 with multiple AMLs (88%) and 9 (50%) with AMLs with epithelial cysts. None of the 15 patients with available clinical follow-up information had evidence of distant metastatic disease from 6 to 198 months after their initial surgery (mean: 52 mo). The 57 RCCs exhibited 3 major distinct morphologies: (1) 17 RCCs (30%) had features similar to tumors previously described as "renal angiomyoadenomatous tumor" or "RCC with smooth muscle stroma"; (2) 34 RCCs (59%) showed features similar to chromophobe RCC; and (3) 6 RCCs (11%) showed a granular eosinophilic-macrocystic morphology. Distinct histologic changes were also commonly present in the background kidney parenchyma and included cysts or renal tubules lined by epithelial cells with prominent eosinophilic cytoplasm, nucleomegaly, and nucleoli. Immunohistochemically, all RCCs tested showed strong nuclear reactivity for PAX8 and HMB45 negativity. Compared with sporadic RCCs, TSC-associated RCCs have unique clinicopathologic features including female predominance, younger age at diagnosis, multiplicity, association with AMLs, 3 recurring histologic patterns, and an indolent clinical course. Awareness of the morphologic and clinicopathologic spectrum of RCC in this setting will allow surgical pathologists to better recognize clinically unsuspected TSC patients.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25093518     DOI: 10.1097/PAS.0000000000000248

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  43 in total

1.  Familial Kidney Cancer: Implications of New Syndromes and Molecular Insights.

Authors:  Maria I Carlo; A Ari Hakimi; Grant D Stewart; Gennady Bratslavsky; James Brugarolas; Ying-Bei Chen; W Marston Linehan; Eamonn R Maher; Maria J Merino; Kenneth Offit; Victor E Reuter; Brian Shuch; Jonathan A Coleman
Journal:  Eur Urol       Date:  2019-07-18       Impact factor: 20.096

Review 2.  New developments in the genetics and pathogenesis of tumours in tuberous sclerosis complex.

Authors:  Hilaire C Lam; Julie Nijmeh; Elizabeth P Henske
Journal:  J Pathol       Date:  2016-11-29       Impact factor: 7.996

3.  "High-grade oncocytic renal tumor": morphologic, immunohistochemical, and molecular genetic study of 14 cases.

Authors:  Huiying He; Kiril Trpkov; Petr Martinek; Ozlem Tanas Isikci; Cristina Maggi-Galuzzi; Reza Alaghehbandan; Anthony J Gill; Maria Tretiakova; Jose Ignacio Lopez; Sean R Williamson; Delia Perez Montiel; Maris Sperga; Eva Comperat; Fadi Brimo; Ali Yilmaz; Kristyna Pivovarcikova; Kveta Michalova; David Slouka; Kristyna Prochazkova; Milan Hora; Michael Bonert; Michal Michal; Ondrej Hes
Journal:  Virchows Arch       Date:  2018-09-19       Impact factor: 4.064

4.  Clear cell papillary renal cell carcinoma and renal angiomyoadenomatous tumor: two variants of a morphologic, immunohistochemical, and genetic distinct entity of renal cell carcinoma.

Authors:  Karl-Friedrich Deml; Hans-Ulrich Schildhaus; Eva Compérat; Adriana von Teichman; Martina Storz; Peter Schraml; Joseph V Bonventre; Falko Fend; Barbara Fleige; Andreas Nerlich; Helmut E Gabbert; Nikolaus GaBler; Rainer Grobholz; Seife Hailemariam; Raoul Hinze; Ruth Knüchel; Benoit Lhermitte; Gabriella Nesi; Thomas Rüdiger; Guido Sauter; Holger Moch
Journal:  Am J Surg Pathol       Date:  2015-07       Impact factor: 6.394

Review 5.  MiT family translocation renal cell carcinomas: A 15th anniversary update.

Authors:  Jatin S Gandhi; Faizan Malik; Mahul B Amin; Pedram Argani; Armita Bahrami
Journal:  Histol Histopathol       Date:  2019-09-06       Impact factor: 2.303

Review 6.  Treatment of renal angiomyolipoma in tuberous sclerosis complex (TSC) patients.

Authors:  S Brakemeier; F Bachmann; K Budde
Journal:  Pediatr Nephrol       Date:  2016-09-01       Impact factor: 3.714

7.  Clear cell clusters in the kidney: a rare finding that should not be misdiagnosed as renal cell carcinoma.

Authors:  José-Antonio Ortiz-Rey; Carmen Fachal; Laura Juaneda-Magdalena; Mónica Muñoz-Martín; Alfredo Repáraz-Andrade; Susana Teijeira; José-María Lamas-Barreiro; Sheila Almuster-Domínguez; Pilar San Miguel-Fraile; Carolina Gómez-de María
Journal:  Virchows Arch       Date:  2021-01-14       Impact factor: 4.064

Review 8.  Thoracoabdominal imaging of tuberous sclerosis.

Authors:  Cara E Morin; Nicholas P Morin; David N Franz; Darcy A Krueger; Andrew T Trout; Alexander J Towbin
Journal:  Pediatr Radiol       Date:  2018-08-04

9.  The classification of pediatric and young adult renal cell carcinomas registered on the children's oncology group (COG) protocol AREN03B2 after focused genetic testing.

Authors:  Mariana M Cajaiba; Lisa M Dyer; James I Geller; Lawrence J Jennings; David George; Dawn Kirschmann; Stephen M Rohan; Nicholas G Cost; Geetika Khanna; Elizabeth A Mullen; Jeffrey S Dome; Conrad V Fernandez; Elizabeth J Perlman
Journal:  Cancer       Date:  2018-06-15       Impact factor: 6.860

Review 10.  [Hereditary renal tumors: More common than expected?].

Authors:  A Agaimy; A Hartmann
Journal:  Pathologe       Date:  2016-03       Impact factor: 1.011

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.